1. Volume 128, Issue 3, Pages 541-551 (March 2005)
Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles 
Liam O’Mahony, Jane McCarthy, Peter Kelly, George Hurley, Fangyi Luo, Kersang Chen, Gerald C. O’Sullivan, Barry Kiely, J. Kevin Collins, Fergus Shanahan, Eamonn M.M. Quigley 
Gastroenterology 
Volume 128, Issue 3, Pages (March 2005)
DOI: /j.gastro
Copyright © 2005 American Gastroenterological Association Terms and Conditions

2. Figure 1
Composite Likert scale and VAS scores. Comparison of the effects of placebo, L salivarius UCC4331, and B infantis on a composite score of IBS symptoms. The scores are derived from the sum of scores for abdominal pain/discomfort, bloating/distention, and bowel movement difficulty. Note the significant reduction in composite scores throughout the treatment period and into the washout phase for subjects treated with B infantis but not with L salivarius UCC4331 or placebo. *P < .05 vs placebo; all comparisons adjusted for any differences in baseline symptom score.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2005 American Gastroenterological Association Terms and Conditions

3. Figure 2
Abdominal pain scores on the Likert scale. Comparison of the effects of placebo, L salivarius UCC4331, and B infantis on abdominal pain/discomfort in IBS. Note the significant reduction in pain/discomfort score during most weeks of the treatment phase and into the washout phase among patients treated with B infantis 35624; for those randomized to L salivarius UCC4331, a significant benefit was evident at week 2 alone. *P < .05 vs placebo; all comparisons adjusted for any differences in baseline symptom score.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2005 American Gastroenterological Association Terms and Conditions

4. Figure 3
Bloating scores on the Likert scale. Comparison of the effects of placebo, L salivarius UCC4331, and B infantis on bloating/distention in IBS. Note the significant reduction in bloating/distention during weeks 2, 5, and 6 for those randomized to B infantis 35624; there was no significant benefit for those randomized to L salivarius UCC4331. *P < .05 vs placebo; all comparisons adjusted for any differences in baseline symptom score.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2005 American Gastroenterological Association Terms and Conditions

5. Figure 4
Bowel movement difficulty scores on the Likert scale. Comparison of the effects of placebo, L salivarius UCC4331, and B infantis on bowel movement difficulty in IBS. Note the significant reduction in bowel movement difficulty during weeks 2, 3, and 5–7 for those randomized to B infantis 35624; there was no significant benefit for those randomized to L salivarius UCC4331. *P < .05 vs placebo; all comparisons adjusted for any differences in baseline symptom score.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2005 American Gastroenterological Association Terms and Conditions

6. Figure 5
PBMC IL-10/IL-12 ratio. Comparison of PBMC IL-10/IL-12 ratios at baseline and following therapy with placebo, L salivarius UCC4331, and B infantis with that of a normal control period. Note the abnormal baseline ratio in subjects with IBS, with a normalization of this ratio following the administration of B infantis alone.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2005 American Gastroenterological Association Terms and Conditions